CD8+CD28− Tregs display functional plasticity in accordance with their microenvironment (e.g., elevated, but defective, in active RA but protective in IBD), suggesting that the targeting or use of these cells will be highly specific for each disease indication. This evidence concerns the gene CD8A and inflammatory bowel disease.